First case of a melanocytic intrabulbar brain tumour treated with bevacizumab

NIMG-18. EFFECT OF BEVACIZUMAB AGAINST CYSTIC PART OF BRAIN TUMOR

(2019) Fumiyuki Yamasaki et al.   NEURO-ONCOLOGY

Use of bevacizumab as a single agent or in adjunct with traditional chemotherapy regimens in children with unresectable or progressive low-grade glioma

(2018) Nataliya Zhukova et al.   Cancer Medicine

Angiogenesis in melanoma: an update with a focus on current targeted therapies

(2016) George Jour et al.   JOURNAL OF CLINICAL PATHOLOGY

Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system

(2016) Johannes van de Nes et al.   JOURNAL OF NEURO-ONCOLOGY

Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma

(2016) A. Ilhan-Mutlu et al.   MOLECULAR CANCER THERAPEUTICS

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

(2014) Pippa G Corrie et al.   LANCET ONCOLOGY

Bevacizumab and central nervous system (CNS) hemorrhage

(2013) Nathalie Letarte et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE